Pablo Corral Shares Insights on Remnant Cholesterol and Its Role in Atherosclerotic Cardiovascular Disease
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Remnant cholesterol: the overlooked driver of residual risk in ASCVD
Despite achieving LDL-C targets with statins and novel lipid-lowering therapies, patients remain exposed to substantial residual cardiovascular risk. Emerging evidence highlights remnant cholesterol (RC)—the cholesterol content of triglyceride-rich lipoproteins—as a causal factor in atherosclerosis.
Epidemiological, genetic, and mechanistic studies consistently show that elevated RC predicts major adverse cardiovascular events, independently of LDL-C. Mendelian randomization confirms a causal role, while clinical data suggest that RC promotes endothelial dysfunction, inflammation, and thrombosis.
Although lifestyle interventions remain essential, pharmacologic strategies—including statins, fibrates, PCSK9 inhibitors, and novel gene-targeted therapies—can reduce RC levels. However, standardized measurement and clear therapeutic targets are still lacking.
RC should be recognized as a priority marker in cardiovascular prevention, guiding future strategies to reduce residual risk in high-risk populations”
Title: A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Authors: Li Wang, Qingmei Zhang, Zhiyang Wu, Xiwei Huang
Read the full article here.
Stay informed with Hemostasis Today.
-
May 6, 2026, 14:20Emmanuel J. Favaloro: Highlights of Global Haemostasis Testing in the Latest Issue
-
May 6, 2026, 14:02Abdul Mannan: Anemia in Myelofybrosis – Five Fires Behind One Falling Hb
-
May 6, 2026, 14:00Mona Alfaraj: Advancing Care in Inherited Platelet Disorders at 2nd International Hematology and Hemostasis Conference
-
May 6, 2026, 13:56Mahesan Subramaniam: Why Delayed Cord Clamping Benefits Newborn Health
-
May 6, 2026, 13:44Wolfgang Miesbach: Octreotide as a First‑Line Systemic Option in VWD Patients With Angiodysplasia‑Related GI Bleeding
-
May 6, 2026, 13:42Irogue Igbinosa: Rethinking Iron Deficiency in Pregnancy with Intravenous Therapy
-
May 6, 2026, 13:34Manaf Aljishi: Three Posters Presented at the Hematology and Hemostasis Conference 2026
-
May 6, 2026, 13:33David Ferreira: Insights from the 1st National Meeting of Young Immunohematologists in Abrantes
-
May 6, 2026, 13:22Nicholas Lee: Honored to Join ASH CRTI Program for Aplastic Anemia Research